AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Aktis Oncology, Inc. Common stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00ZQS8L07
15.73▼ 1.03 (-6.15%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
16.76
Day's Range
15.65 – 16.61
52-Week Range
14.56 – 34.19
Volume
236.1K
Avg Volume
460.3K
Share Statistics
Shares Outstanding
Employees
79
Exchange
XNAS
Listed
2026-01-09
Share count as of July 31, 2026

Aktis Oncology, Inc. Common stock (AKTS) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Aktis Oncology, Inc. Common stock (AKTS)
What is Aktis Oncology, Inc. Common stock's Market Cap?
Aktis Oncology, Inc. Common stock's Market Cap is $874.9M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AKTSAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Jun 30, 2025Mar 31, 2025
Revenue:
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue954.0%803.6%
Loss from operations
% of revenue-854.0%-703.6%
Other income (expense):
Interest income
Other expense, net
Total other income, net
Net loss
% of revenue-713.5%-567.9%
Net loss per share of common stock, basic
Net loss per share of common stock, diluted